

Intra-Cellular Therapies to Present at the 54th Annual Meeting of the American College of Neuropsychopharmacology

NEW YORK, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced two ITI-007 poster presentations at the 54th Annual Meeting of the American College of Neuropsychopharmacology being held in Hollywood, Florida, December 6-10, 2015.

The poster presentation (Abstract W166), titled "Clinical Development of ITI-007 for the Treatment of Schizophrenia," will take place on Wednesday, December 9, 2015, 5:30 pm - 7:30 pm ET during Poster Session III.

The poster presentation (Abstract W174), titled "Further Characterizing Brain Receptor Occupancy with ITI-007: Results from a Positron Emission Tomography (PET) Study in Patients," will also take place on Wednesday, December 9, 2015, 5:30 pm - 7:30 pm ET during Poster Session III.

About Intra-Cellular Therapies

CONTACT: Juan Sanchez, M.D.

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media)

212-213-0006

O Intra-Cellular Therapies

Source: Intra-Cellular Therapies, Inc.

News Provided by Acquire Media